Daniela Gebauer
Tel. +49 (0) 89-2000 339-13
gebauer@goingpublic.de
Katharina Meindl
Tel. +49 (0) 89-2000 339-53
meindl@goingpublic.de
Karin Hofelich
Tel. +49 (0) 89-2000 339-54
karin.hofelich@goingpublic.de
Tel. +49 (0) 177-422 52 89
Contact media sales team
Publication date:
February 25
th
, 2012
Special
Industrial Biotechnology 2012 (Vol. 3)
Publication date:
March 31
st
, 2012
Supplement
Healthcare 2012 (Vol. 6)
Publication date:
June 30
th
, 2012
Advertising close:
June 18
th
, 2012
Special Topic Life Science in
GoingPublic Magazin 7/2012
Publication Date:
September 15
th
, 2012
Advertising close:
September 3
rd
, 2012
Special edition
Biotechnology 2012 (Vol. 14)
Publication date:
November 14
th
, 2012
Advertising close:
November 2
nd
, 2012
Supplement
Medical Technology 2012 (Vol. 10)
Only GoingPublic Magazin’s Special “Industrial Biotechnology”
is published in English, all others in German.
Further info: www.goingpublic.de
GoingPublic´s
classic
Expertise in Life Sciences
24
BioTOPics 44 | May 2012
BioTOP-Report
Life Sciences
Excellent Research in Berlin-Brandenburg
Berlin-Brandenburg is regarded both nationally and internationally as one of the most important centers of
modern biotechnology. The region provides optimal conditions: It is one of the TOP life sciences locations
worldwide – with five universities, numerous colleges and a unique density of extramural research centers.
Renowned facilities in the field of biotechnology and the life sciences include four Max Planck Institutes, two
Fraunhofer Institutes, two Leibniz Institutes and two Helmholtz Association centers. The region also has an
abundant landscape of clinics, led by the Charité – Universitätsmedizin Berlin.
Biotechnology is a major contributor to the development of the
modern life sciences. It is highly interdisciplinary, encompass-
ing pharmaceutics research, diagnostics, theranostics, molecu-
lar genetics and the development of innovative biomaterials
for medical applications. In addition to scientific expertise, the
Berlin-Brandenburg region offers excellent conditions for close
networking between different science disciplines, research cen-
ters, industry and (clinical) users.
No less than seven technology parks focusing on the life sciences
are situated in the region (see p. 18-22). One of Germany’s larg-
est biotechnology parks is Campus Berlin-Buch, with important
facilities such as the Max Delbrück Center for Molecular Medicine
(MDC), which is part of the Helmholtz Association, and the Leib-
JANUARY 2011
Prof. Dr. Andreas Radbruch of the German Rheumatism Research Center Ber-
lin (DRFZ) receives Advanced Grant of the European Research Council (ERC)
in the amount of 2.5 million Euro
++++
Prof. Dr. Klaus Rajewsky receives
Advanced Grant of the European Research Council (ERC) in the amount of 2.5
million Euro and establishes working group at the MDC
FEBRUARY 2011
ESGI project (the European Sequencing and Genotyping Infrastructure), coor-
dinated by the Max-Planck-Institute for Molecular Genetics, starts
MARCH 2011
Charité-scientist Andrea Ode of the Julius Wolff Institute wins BIONNALE
Speed Lecture Award
++++
Prof. Dr. Oliver Daumke from the Max Delbrück
Center for Molecular Medicine (MDC) Berlin-Buch receives “Bayer Early Excel-
lence in Science Award 2010” for biology
APRIL 2011
Berlin research consortium becomes part of the German Center for
Cardiovascular Research (DZHK)
++++
Dr. Daniel Toben of Charité receives
Raisz-Drezner-Award of the American Society of Bone and Mineral Research
(ASBMR)
++++
BioTOP and BCRT publish technology
report on Regenerative
Medicine in Berlin-Brandenburg
++++
Prof. Dr. Jan Schwab of the Department
of Neurology at the Charité and the Berlin-Brandenburg Center for Regenera-
tive Therapies (BCRT) received the Novartis Award for therapy relevant phar-
macological research
MAY 2011
Researchers at the Max Delbrück Center for Molecular Medicine (MDC) Berlin-
Buch of the Helmholtz Association have discovered what it is that enables
embryonic stem cells to develop into the most diverse cell types and hence be
pluripotent
++++
An international team around researchers
at the Max Planck
Institute of Colloids and Interfaces in Potsdam has developed a vaccine based
on a carbohydrate against the bacterium Clostridium difficile, which causes
severe intestinal infections especially in hospitals
JUNE 2011
The MDC, Charité and German Heart Institute Berlin (DHZB) are appointed as
the Berlin sites for the German Centers for Cardiovascular Research (DZHK)
++++
Andreas Radbruch, Science Director of the German Rheumatism
Research Center (DRFZ), receives the world’s most prestigious rheumatol-
ogy award, the Carol-Nachman Prize, for his research into the immunological
memory for inflammatory-rheumatic diseases
Prof. Dr. Volker Haucke
Scientific Director of the Leibniz Institute
for Molecular Pharmacology (FMP)
We are experiencing exciting times in Berlin and at the Cam-
pus Buch, where biology, pharmacology, and chemistry meet
– with the FMP serving as a melting pot. The Campus and the
FMP have gained a lot of international recognition over the
last years and serve as a magnet for top scientists from all
around the globe.